Navigation Links
Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million

DENVER, Oct. 6 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that the company has been successful in securing a $1,750,000 credit facility providing initial funding of $1,109,000 in an asset based financing from Summit Financial Resources L.P. This financing allowed for the retirement of the company's factoring line of credit with Benefactor Funding Corp., and will be used for working capital purposes.

The agreement with Summit initially has a term of three years. Under the agreement, the company has the ability to borrow up to $1.75 million in cash secured by accounts receivable, inventory and other assets.

"This transaction, which is the culmination of many weeks of discussions with the Summit team, is a vital element in furthering the execution of our strategic plan," stated William Critchfield, Senior Vice President and Chief Financial Officer of Corgenix. "The new financing allows us to retire the existing factoring line, provides us with a fresh infusion of cash, and further provides us much greater financial flexibility and growth potential going forward."

Gordon La Haye, President & CEO of Summit Financial Resources, commented, "Summit is very pleased that Corgenix has chosen to replace their existing line with our working capital facility. We look forward to helping them achieve their growth objectives with this new, more flexible credit line." The Summit Financial Resources team was led by Renee Jackson, VP, Business Development Officer for the Intermountain Region, based in Denver.

"We have been extremely impressed by the professionalism and the very organized approach put forth by Summit," stated Critchfield. "Summit's asset size along with the broad expertise possessed by their management and lending team is very impressive. The fact that they were equally excited to have Corgenix as a portfolio company, after their having performed extremely comprehensive due diligence on our company, bodes very well for the future of our Company."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at

About Summit Financial Resources L.P.

Summit Financial Resources is a nationally recognized provider of working capital financing to small and medium-sized businesses in a broad range of industries. With 16 offices nationwide and over 20 years of experience, Summit has established itself as one of the largest and fastest growing companies in its industry.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation

SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
10. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
11. Corgenix to Host Conference Call to Discuss First Quarter Results
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  CardioCell LLC, a ... stem cells for cardiovascular indications, intends to proceed ... based on recommendations from a Heart Failure Advisory ... Scientific Advisory Board members . In a ... Phase IIa safety and efficacy data from CardioCell,s ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... marketing company specializing in scientifically backed, age-defying products, is featured as the ... highlights the exponential success and unrivaled opportunities that Nerium provides. Success from ...
(Date:12/1/2015)... 1, 2015 Dr. Harry Lander , President of Regen, ... Chief Science Officer and recruits five distinguished ... , President of Regen, expands his role to include ... recruits five distinguished scientists to join advisory team ... his role to include serving as Chief ...
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
Breaking Biology Technology:
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):